新型长效口服贝前列素对肺动脉高压患者短期疗效的初步研究。
Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension.
作者信息
Ikeda Daisuke, Tsujino Ichizo, Sakaue Shinji, Ohira Hiroshi, Itoh Naofumi, Kamigaki Mitsunori, Ishimaru Shinji, Atsumi Tatsuya, Nishimura Masaharu
机构信息
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
出版信息
Circ J. 2007 Nov;71(11):1829-31. doi: 10.1253/circj.71.1829.
BACKGROUND
Oral prostacyclin analogs can improve the prognosis of patients with mild to moderate pulmonary arterial hypertension (PAH), but because they often provoke adverse effects, such as flushing and dizziness, administering the optimal dose can be difficult.
METHODS AND RESULTS
In the present study, a novel long-acting oral beraprost (TRK-100STP: 0-360 mug/day for 12 weeks) was administered to 4 patients with mild to moderate PAH. The patients tolerated the drug well with mild adverse manifestations and negligible effects on the systemic circulation. In contrast, pulmonary vascular resistance decreased by 27+/-12% and the 6-min walk test distance increased by 11+/-11%.
CONCLUSIONS
TRK-100STP is a novel option in the medical management of patients with PAH.
背景
口服前列环素类似物可改善轻至中度肺动脉高压（PAH）患者的预后，但由于它们常引发不良反应，如脸红和头晕，因此难以给予最佳剂量。
方法与结果
在本研究中，对4例轻至中度PAH患者给予了一种新型长效口服贝拉前列素（TRK-100STP：0 - 360微克/天，持续12周）。患者对该药物耐受性良好，不良反应轻微，对体循环的影响可忽略不计。相比之下，肺血管阻力降低了27±12%，6分钟步行试验距离增加了11±11%。
结论
TRK-100STP是PAH患者药物治疗的一种新选择。
Zotero 插件